As of November 6, 2026, Zenas BioPharma, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on August 13, 2026, naming 1 appointment. The latest filing names Christy J. Oliger, appointed (Form 8-K, August 13, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Zenas BioPharma, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Zenas BioPharma, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-08-13. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Zenas BioPharma, Inc. files it.
Also on the record for Zenas BioPharma, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 5, 2026 | Stake report, Schedule 13G/A, by Xencor, Inc. | 1.5% of the class | 5%+ stakes | Source |
| October 27, 2026 | Stake report, Schedule 13G, by BlackRock, Inc. | 5% of the class | 5%+ stakes | Source |
| September 8, 2026 | Stake report, Schedule 13G, by Wellington Management Group LLP | 10.1% of the class | 5%+ stakes | Source |
| September 8, 2026 | Stake report, Schedule 13G/A, by InnoCare Pharma Inc. | 10.4% of the class | 5%+ stakes | Source |
| August 19, 2026 | Stake report, Schedule 13D/A, by Enavate Sciences GP, LLC | 4.9% of the class | 5%+ stakes | Source |
| August 17, 2026 | Stake report, Schedule 13D/A, by SR One Capital Management, LLC | 7.7% of the class | 5%+ stakes | Source |
| May 5, 2026 | Stake report, Schedule 13D, by MOULDER LEON O JR | 5.09% of the class | 5%+ stakes | Source |
| April 2, 2026 | Stake report, Schedule 13D/A, by Leon O. Moulder, Jr. | 4.794% of the class | 5%+ stakes | Source |
| February 5, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 14.3% of the class | 5%+ stakes | Source |
| January 14, 2026 | Stake report, Schedule 13D, by Leon O. Moulder, Jr. | 5.159% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by Novo Holdings A/S | 4.7% of the class | 5%+ stakes | Source |
| October 15, 2025 | Stake report, Schedule 13G, by InnoCare Pharma Inc. | 9.4% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Zenas BioPharma, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Zenas BioPharma, Inc. and the records around it.
Zenas BioPharma, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Who owns it
Companies that share a holder
- Enavate Sciences GP, LLC also filed stake reports on 2 other companies: CAMP4 THERAPEUTICS CORPORATION (Mar 2026)
- Longitude Capital Partners IV, LLC also filed stake reports on 2 other companies: Lexeo Therapeutics, Inc. (Nov 2025), CG Oncology, Inc. (Sep 2025)
- SR One Capital Management, LLC also filed stake reports on 6 other companies: ADARx Pharmaceuticals, Inc. (Oct 2026), Veradermics, Inc. (Aug 2026), Odyssey Therapeutics, Inc. (May 2026)
Watch Zenas BioPharma, Inc.
Get an email when Zenas BioPharma, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Zenas BioPharma, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Zenas BioPharma, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Zenas BioPharma, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 21 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-08-13 | In | 8-K, 2026-08-13 |
New leaders reset buying decisions — get the Full Report on Zenas BioPharma, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Zenas BioPharma, Inc., with the record behind each one.
Find candidates like senior executive at Zenas BioPharma, Inc.Every change, in the filing's words
Appointed: Christy J. Oliger
Effective on the Appointment Date, Ms. Oliger will serve as a member of the Nominating and Corporate Governance Committee of the Board and the Science and Technology Committee of the Board, to serve in accordance with the respective Committee's charters and until her earlier resignation or removal.
- Appointment of Christy J. Oliger Upon the recommendation of the Nominating and Corporate Governance Committee of the Company's Board of Directors (the "Board"), on August 12, 2026, the Board appointed Christy J. Oliger to serve on the Board as a Class II director to hold office until the Company's annual meeting of stockholders in 2029 and until her successor is duly elected and qualified, or her earlier death, resignation or removal, with such appointment to be effective as of September 1, 2026 (the "Appointment Date").
- The Board determined that Ms. Oliger is independent under the applicable listing standards of the Nasdaq Global Select Market.
- In connection with this appointment, the Board increased the authorized size of the Board by one, effective as of the Appointment Date.
Tools for this story
Each opens in a new tab, filled in for Zenas BioPharma, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.